Cystic Fibrosis-Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a009548. doi: 10.1101/cshperspect.a009548.
Technological advances in genetics have made feasible and affordable large studies to identify genetic variants that cause or modify a trait. Genetic studies have been carried out to assess variants in candidate genes, as well as polymorphisms throughout the genome, for their associations with heritable clinical outcomes of cystic fibrosis (CF), such as lung disease, meconium ileus, and CF-related diabetes. The candidate gene approach has identified some predicted relationships, while genome-wide surveys have identified several genes that would not have been obvious disease-modifying candidates, such as a methionine sulfoxide transferase gene that influences intestinal obstruction, or a region on chromosome 11 proximate to genes encoding a transcription factor and an apoptosis controller that associates with lung function. These unforeseen associations thus provide novel insight into disease pathophysiology, as well as suggesting new therapeutic strategies for CF.
遗传学领域的技术进步使得进行大规模研究以鉴定导致或改变特征的遗传变异成为可能且负担得起。已经开展了遗传研究,以评估候选基因中的变异以及整个基因组中的多态性,以评估它们与囊性纤维化 (CF) 的可遗传临床结果(如肺部疾病、胎粪性肠梗阻和 CF 相关糖尿病)的关联。候选基因方法已经确定了一些预测的关系,而全基因组调查则确定了几个原本不会成为明显的疾病修饰候选基因,例如影响肠梗阻的蛋氨酸亚砜转移酶基因,或 11 号染色体上靠近编码转录因子和凋亡控制器的区域,与肺功能相关。这些意外的关联为疾病的病理生理学提供了新的见解,并为 CF 提出了新的治疗策略。